A market research study utilizing NeutraSal (supersaturated calcium phosphate oral rinse) as a treatment for xerostomia in subjects with Sjögren's syndrome found that 90% of the subjects were satisfied with the medication with no adverse effects, according to Invado Pharmaceuticals.
Forty subjects (39 female, 1 male) with a median age of 59.4 years with a previous diagnosis of primary or secondary Sjögren's syndrome and subsequent xerostomia agreed to evaluate the efficacy of NeutraSal for 28 days. Subjects at baseline were given a dry mouth questionnaire and asked to complete a self-assessment 28 days later. Results were compared with the baseline questions.
Patients on average reported dryness of mouth of 3.7 and dryness of the tongue of 4.0 based on a scale of 1 to 10 (1 = "dry as desert," 10 = normal).
NeutraSal use showed a dramatic improvement in symptomatic relief of xerostomia based on the dry mouth questionnaire, Invado reported. The average score for dryness of the mouth improved from 3.6 to 8.2 and for the tongue from 4.0 to 8.1, based on the 10-point scale.
